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What is holding the 







Introduction of new technologies
Marked expectations – Results form Continuous BioProcessing survey 
Authorities expectations 














Guided Decision Process for SUS
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• Size, pressure, 
temperature 
limitations
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• Is the relevant 
equipment 
available?
• Complexity of 
the system
• PAT tools 
developed
• Return of 
investment








• CQAs affected 
• Cell viability / 
productivity


























• Tech transfer 





• Supplier reliability 
• Facility operation –
24/7
• Start-up and shut-
down situations
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Delta 2: The possible 
future benefit 
Delta 1: The needed 
investment / mountain to pass
Reduce the activation energy
The aim is to 
reduce ∆1 and 
increase ∆2






Marked requirements to pharma engineering
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“Help us ensure we can 
always deliver to demands in 
more agile and flexible 
ways
“Help us build and maintain 
quality systems and solutions 
that can ensure the right  
level of compliance
“Help us build the expertise 
required when introducing 
new drug categories 
or technologies
Sites need to ensure 
they can always adapt 
and deliver to changing 
demands
Sites need well-integrated 
and balanced quality 
solutions
Sites need to quickly absorb 
knowledge to implement 
new practises
Operational Issues Associated with CBP
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Logistics benefits and challenges
PAT or QbD issues
Quality Control Issues in CBP
Quality systems required for CBP vs batch
GMP Issues in CBP
Survey performed by BioPlan Associates, for NNE Pharmaplan
Need for CBP Case Studies
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Supplier Case Studies: (e.g., GE, SSB, Thermo, Lonza, CMC)
CBP in development scale
Transitioning from small scale to large scale
Industry adaptation of Current CBP
Factors Contributing to Failures in adopting CBP
End-user Case Studies: What real CBP solutions look like
How to successfully implement CBP
Survey performed by BioPlan Associates, for NNE Pharmaplan
What is currently holding back implementation of CBP?
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• Precedence - someone else needs get it through the FDA/EMA first
• Robust PAT tools, defined regulatory path, robust single use technology
• Comfort level and lack of PAT and control tools 
• CBP doesn't easily fit into existing infrastructure / facilities / Quality systems 
• Economic justification and adaptation of current Quality/Regulatory programs
• Unit operations not fully developed for continuous processing; not a standard 
platform 
Survey performed by BioPlan Associates, for NNE Pharmaplan
12 http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM341197.pdf
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SUB 1000L Depth filtration Harvest hold ProA IEX 1 IEX 2 VF UF/DF1 Bulk Filtration
Degree of Continuous Bioprocessing (CBP)
Batch process 
SUB 1000L Depth filtration Harvest hold ProA IEX 1 IEX 2 VF UF/DF1 Bulk Filtration
Batch process and 
USP CBP
ProA IEX 1 IEX 2 VF UF/DF1 Bulk FiltrationSUB 1000L Depth filtration Harvest hold
Batch process and 
DSP CBP
IEX 1 IEX 2 VF UF/DF1 Bulk FiltrationSUB 1000L Depth filtration Harvest hold ProA
USP and DSP CBP
Facility design and operation – Batch vs CBP
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Batch
• Possible to be operated in 1 or 2 shifts, 5 days
• Can be based on manual operation
• Separate USP and DSP teams
• Some advantage of PAT
• Possible re-use of equipment in different steps
• Large vessels for hold steps
• Large buffer vessels and process equipment
• Process steps independent
• Less impact due to delay or failure in one step
• Manufacturing can be separated from Dev, QC 
and QA
• Facility designed based on scale up
• X productivity per m2 facility area
• Product quality and process reproducibility 
CBP
• Need 24/7 operation
• High level of automation required
• One team
• PAT a requirement 
• All equipment dedicated to each step
• No or limited hold steps needed 
• Smaller equipment both USP and DSP
• The process steps need to be in synchronized 
• The whole process stops if one step stops
• Dev, QC and QA need to be close /integrated in 
the manufacturing facility
• Facility designed based on scale out
• 5 to 15 X productivity per m2 facility area




• Shorter contact time
• Time at 37°C in complex media – 14 days vs 3 days
• Protein/resin interaction – hours vs minutes
• Shorter processing time
• Less/shorter intermediate hold times
• Real time process control 
• Fast response time to process drifting and deviations
• Generation of large amount of data 
• Option for increased process understanding           Increased Process Control
• Option for real time release
• Build in quality vs testing in quality 
• Increased reproducibility and control
• Aim for a state of “in control” rather “steady-state” conditions 
Compliance  
Stepwise Approach - Start in the development lab!
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• Taking advantage of CBP in development do 
not require to run manufacturing in CBP mode
• Column life time studies
• Testing parameter ranges in one set up 
• Generate knowledge of relationship between 
CQA’s and CPP’s
• Basis for feed-forward and feed-backward 
controls    
• Perfusion rate impact on viable cell conc, 
Elution conductivity impact on pool volume   
• Identify Critical Process Indicators (CPI)
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Are others considering CBP ?
Conclusions
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• The science exists to enable continuous manufacturing of pharmaceuticals
• Still specific scientific and technical challenges to be addressed 
• There shouldn't be unmanageable regulatory hurdles precluding 
implementing continuous manufacturing
• However, there is a lack of experience both in industry and within the 
regulatory authorities
• FDA supports the implementation of continuous manufacturing using a 
science and risk-based approach
• Advisable to use a structured and stepwise approach 
• Develop processes using and a QbD and PAT approach, as this will 
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